Comparative Pharmacology
Head-to-head clinical analysis: MECLOMEN versus TOLECTIN 600.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLOMEN versus TOLECTIN 600.
MECLOMEN vs TOLECTIN 600
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclomen (meclofenamate) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This results in anti-inflammatory, analgesic, and antipyretic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
50-100 mg orally every 6-8 hours; maximum 400 mg/day.
600 mg orally three times daily; maximum 1800 mg/day.
None Documented
None Documented
Terminal elimination half-life: 0.8–1.1 hours for meclofenamic acid; 2–4 hours for metabolites. Short half-life requires frequent dosing (e.g., every 6–8 hours) for sustained effect.
Terminal elimination half-life is approximately 5 hours (range 4-6 hours) in healthy adults; prolonged in renal impairment.
Renal (approximately 70% as metabolites, <5% unchanged); fecal/biliary (approximately 30% as metabolites).
Renal: approximately 90% as metabolites and conjugates; biliary/fecal: minor (less than 10%)
Category C
Category C
NSAID
NSAID